مقاله انگلیسی رایگان در مورد تمایل والدین برای واکسیناسیون دختر خود در برابر ویروس پاپیلومای انسانی – الزویر 2021

Abstract

Keywords

1. Introduction

2. Methods and materials

3. Result

4. Discussion

5. Conclusion and recommendations

Declarations

Acknowledgements

References

Abstract

Background
In Ethiopia, the human papillomavirus vaccine has been introduced since 2018. Since the vaccination program targets girls age 9–13, the success of vaccination depends on the parental decision and their willingness to vaccinate their daughters. Therefore, a study on parental willingness to vaccinate their daughter and factors associated is needed.

Objective
To assess parent’s willingness to vaccinate their daughter against the human papillomavirus and its associated factors in Bench-Sheko Zone, southwest Ethiopia.

Methods
A community-based cross-sectional study was conducted among 502 participants in Bench-Sheko Zone, southwest Ethiopia. The participants were selected using a systematic random sampling method. Frequency tables, mean and standard deviation were used to summarize the data. A binary logistic regression using bivariate and multivariable logistic regression analysis was used to identify factors associated with parental willingness to vaccinate their daughter. The level of significance was declared at P-value < 0.05.

Results
Of the 502 participants interviewed, 399 (79.5%), 95% CI (76%, 83%) of parents were willing to vaccinate their daughter. The study found that primary education and above (AOR = 2.9, 95% CI [1.79, 4.95]), having good knowledge (AOR = 2.1, 95% CI [1.15, 4.10]) and positive attitude (AOR = 2, 95% CI [1.30, 3.41]) were significantly associated with parental willingness to vaccinate their daughter.

Conclusion
This study found that there was a high parental willingness to vaccinate their daughter against the human papillomavirus in the study area. Primary education and above, having good knowledge and positive attitude were factors associated with parental willingness to vaccinate their daughter. Therefore, providing health information’s regarding human papillomavirus vaccination with emphasis to raise community awareness should be designed especially less educated parents need to be targeted.

1. Introduction

Cervical cancer is the fourth most common cancer diagnosed among women worldwide [[1]]. More than 80% of the cases are in developing countries [[1]]. In Ethiopia, cervical cancer becomes the second leading cause of cancer death [[1]]. Cervical cancer prevention programs such as HPV vaccination and cytology-based cervical cancer screening programs decreased cervical cancer incidence in developed countries [[2]]. However, in developing countries, lack of access to effective screening and low screening coverage, poverty, low education, and life in rural areas [[3], [4]] coupled with a high incidence of HPV 16 and 18 infections [[5]] increases cervical cancer incidence.

Persistent human papillomavirus (HPV) infection, a sexually transmitted disease, is identified as the necessary cause of cervical cancer particularly HPV 16, 18, and 31 serotypes [[6], [7]]. More than 80% of sexually active women are infected by HPV at least once during their lifetime [[8]]. In response to this, the world health organization develops comprehensive strategies for the prevention and control of cervical cancer including HPV vaccination as the primary prevention method for cervical cancer [[9]]. Three HPV vaccines namely bivalent (Cervarix, GlaxoSmithKline), quadrivalent (Gardasil, Merck), and nonavalent (Gardasil, Merck) vaccines are currently available, and have proven effective at protecting against HPV 16 and HPV 18 infections [[10]]. which are currently approved for vaccination in developing countries by WHO [[11]]. In Ethiopia, HPV vaccine with the support of the Global Alliance for Vaccine and Immunization (GAVI) has been introduced since 2018 being delivered through a school-based approach [[12]] as Ethiopia fulfilled the GAVI Alliances eligibility criteria for HPV vaccination support [[13]]. WHO recommends the vaccination to girls of age 9–13 years old [[14]].